全文获取类型
收费全文 | 3546篇 |
免费 | 270篇 |
国内免费 | 129篇 |
专业分类
耳鼻咽喉 | 81篇 |
儿科学 | 46篇 |
妇产科学 | 60篇 |
基础医学 | 608篇 |
口腔科学 | 23篇 |
临床医学 | 193篇 |
内科学 | 472篇 |
皮肤病学 | 50篇 |
神经病学 | 90篇 |
特种医学 | 48篇 |
外科学 | 377篇 |
综合类 | 232篇 |
预防医学 | 121篇 |
眼科学 | 15篇 |
药学 | 239篇 |
1篇 | |
中国医学 | 8篇 |
肿瘤学 | 1281篇 |
出版年
2024年 | 8篇 |
2023年 | 172篇 |
2022年 | 316篇 |
2021年 | 361篇 |
2020年 | 303篇 |
2019年 | 252篇 |
2018年 | 209篇 |
2017年 | 199篇 |
2016年 | 152篇 |
2015年 | 122篇 |
2014年 | 156篇 |
2013年 | 154篇 |
2012年 | 142篇 |
2011年 | 152篇 |
2010年 | 126篇 |
2009年 | 114篇 |
2008年 | 104篇 |
2007年 | 136篇 |
2006年 | 115篇 |
2005年 | 102篇 |
2004年 | 80篇 |
2003年 | 72篇 |
2002年 | 53篇 |
2001年 | 43篇 |
2000年 | 50篇 |
1999年 | 29篇 |
1998年 | 27篇 |
1997年 | 38篇 |
1996年 | 22篇 |
1995年 | 33篇 |
1994年 | 22篇 |
1993年 | 15篇 |
1992年 | 9篇 |
1991年 | 6篇 |
1990年 | 9篇 |
1989年 | 7篇 |
1988年 | 3篇 |
1987年 | 4篇 |
1986年 | 4篇 |
1985年 | 3篇 |
1983年 | 1篇 |
1982年 | 7篇 |
1981年 | 4篇 |
1980年 | 3篇 |
1979年 | 1篇 |
1977年 | 3篇 |
1976年 | 1篇 |
1974年 | 1篇 |
排序方式: 共有3945条查询结果,搜索用时 62 毫秒
61.
《Best Practice & Research: Clinical Haematology》2018,31(2):176-183
Chimeric antigen receptors (CAR)-T cell therapy has recently made promising advances towards treatment of B-cell malignancies. This approach makes use of an antibody-derived single chain variable fragment (scFv)-based CAR to target the CD19 antigen. Currently scFvs are the most common strategy for creation of CARs, but tumor cells can also be targeted using non-antibody based approaches with designs focused on the interaction between natural receptors and their ligands. This emerging strategy has been used in unique ways to target multiple tumor types, including solid and haematological malignancies. In this review, we will highlight the performance of receptor-ligand combinations as designs for CARs to treat cancer, with a particular focus on haematologic malignancies. 相似文献
62.
Several drugs have demonstrated clinical activity in metastatic renal cell carcinoma (mRCC). The identification of key metabolic pathways has led to the development of novel targeted therapies which have drastically changed the treatment paradigm of mRCC. Moreover, immune-checkpoint inhibitors have recently shown significant activity in advanced disease. Despite these advancements, the role of adjuvant therapy in localized, non-metastatic RCC remains unclear. The utility of many of these agents in the adjuvant setting is currently being actively explored. In this review, we will summarize the main clinical trials investigating adjuvant therapy in renal cell carcinoma, focusing primarily on immunotherapy and targeted agents. 相似文献
63.
转移性肾癌免疫治疗研究进展 总被引:1,自引:0,他引:1
转移性肾癌对传统放、化疗均不敏感,目前尚缺乏有效的治疗手段.IL-2和IFN-α是目前研究较多的细胞因子制剂,但单独应用于转移性肾癌患者的治疗时效率低.近年来,随着分子免疫机制的研究进展,疫苗、过继免疫治疗的研究发展迅速,特别是树突状细胞疫苗(DC vaccine)和自体细胞因子诱导的杀伤细胞(CIK)的研究取得了很大的进展. 相似文献
64.
肝细胞癌是原发性肝癌的主要病理类型,目前的临床治疗方法难以达到理想的效果,迫切需要探索新的、有效的治疗方法。T细胞受体基因工程改造T细胞(TCR-T)疗法因在实体瘤中的成功应用,被认为是最有前景的免疫治疗方式之一。本文主要从TCR-T治疗在肝细胞癌中的研究进展进行综述,并针对性提出一些解决策略,包括优化TCR亲和力、降低毒性反应、减少外源性和内源性TCR双链错配、改善肿瘤微环境、促进TCR-T细胞扩增。 相似文献
65.
《Acta oto-laryngologica》2012,132(1):54-60
The most common cause of seasonal allergic rhinitis in Japan is the Japanese cedar (JC). Recently, a pullulan-conjugated antigen (CS-560) has been developed to reduce adverse effects and to enhance the effect of JC-specific immunotherapy (IT). If the mechanism of IT can be fully elucidated and the treatment can be used safely and with specificity, IT should be reconsidered as a superior treatment for JC pollinosis. Thirteen patients with JC pollinosis who received IT were compared to 10 patients who did not receive IT. All patients were followed through two pollen seasons by means of allergy diaries. Peripheral blood mononuclear cells (PBMC) were collected before IT and just before each pollen season, and these were stimulated with pollen extract. The concentrations of IL-4, IL-5, IL-13 and IFN- n in the culture supernatants were determined using an ELISA. Furthermore, messenger (m)RNA expressions of IL-4 and IL-5 from cultured PBMC were also studied. As a result of the allergy diaries, we confirmed the clinical efficacy of CS-560. The symptom-medication scores were significantly decreased by IT. The levels of IL-4, IL-5 and IL-13 declined only in the IT group. However, the level of IFN- n did not change in either group. IL-4 and IL-5 mRNA expressions were inhibited in the IT group compared to that in the non-IT group. In conclusion, specific IT for JC pollinosis using CS-560 clearly modified cytokine expression by PBMC. 相似文献
66.
《Best Practice & Research: Clinical Haematology》2018,31(3):299-305
The idea that the immune system could be co-opted to treat cancer is not new; it has existed for centuries. However, what is new is the advancement of our understanding of how the immune system is regulated and how a tumor evolves to evade an immune response. This knowledge, combined with modern technologies to manipulate the immune system, both pharmacologically and genetically, has led to the realization of immuno-oncology as a new frontier in cancer therapeutics. This review will focus on pharmacologic immunotherapies in aggressive B cell lymphomas: checkpoint inhibition and bispecific antibodies. The success of checkpoint inhibitors in this heterogenous collection of diseases has largely been limited to those that genetic aberrations involving genes for checkpoint ligands, whereas bispecific antibodies appear to be more broadly efficacious but responses are short-lived. Investigation into the tumor microenvironment for each of the aggressive B cell lymphoma histologies, and interrogation of mechanisms of resistance as well as predictors of response to these immunotherapy approaches, will undoubtedly identify rational combinations as well as new therapeutic targets such that outcomes can be improved across these diseases. 相似文献
67.
68.
69.
《Current problems in cancer》2018,42(6):530-547
Although developments in the diagnosis and therapy of colorectal cancer (CRC) have been made in the last decade, much work remains to be done as it remains the second leading cause of cancer death. It is now well established that epigenetic events, together with genetic alterations, are key events in initiation and progression of CRC. Epigenetics refers to heritable alterations in gene expression that do not involve changes in the DNA sequence. These alterations include DNA methylation, histone alterations, chromatin remodelers, and noncoding RNAs. In CRC, aberrations in epigenome may also involve in the development of drug resistance to conventional drugs such as 5-fluorouracil, oxaliplatin, and irinotecan. Thus, it has been suggested that combined therapies with epigenetic agents may reverse drug resistance. In this regard, DNA methyltransferase inhibitors and histone deacetylase inhibitors have been extensively investigated in CRC. The aim of this review is to provide a brief overview of the preclinical data that represent a proof of principle for the employment of epigenetic agents in CRC with a focus on the advantages of combinatorial therapy over single-drug treatment. We will also critically discuss the results and limitations of initial clinical experiences of epigenetic-based therapy in CRC and summarize ongoing clinical trials. Nevertheless, since recent translational research suggest that epigenetic modulators play a key role in augmenting immunogenicity of the tumor microenvironment and in restoring immune recognition, we will also highlight the recent developments of combinations strategies of immunotherapies and epigenetic therapies in CRC, summarizing preclinical, and clinical data to signify this evolving and promising field for CRC treatment. 相似文献
70.